ZOCOR (simvastatin) by Merck & Co. is hydroxymethylglutaryl-coa reductase inhibitors [moa]. First approved in 1991.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
ZOCOR (simvastatin) is an oral HMG-CoA reductase inhibitor (statin) approved in 1991 that lowers cholesterol by inhibiting hepatic cholesterol synthesis. It is used to reduce cardiovascular risk in patients with elevated LDL cholesterol and dyslipidemia. Simvastatin remains a foundational therapy in lipid management despite the emergence of newer statin classes.
Declining Part D spending and approaching loss of exclusivity signal a shrinking brand team and shift toward lifecycle extension or deprioritization strategies.
Hydroxymethylglutaryl-CoA Reductase Inhibitors
HMG-CoA Reductase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
Bioequivalence Study of Simvastatin 40 mg Film-coated Tablets in Healthy Thai Volunteers
Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
Worked on ZOCOR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZOCOR offers limited career growth due to mature lifecycle stage and minimal linked job openings; positions focus on defensive strategy, generic transition management, and cost-of-goods optimization. Working on this product suits professionals seeking stable, maintenance-focused roles rather than growth trajectories.